Chengdu Olymvax Biopharmaceuticals Inc.

688319

CNE1000051H8

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-06-13 pm EDT			5-day change	1st Jan Change
10 ^CNY	-2.63%		0.00%	-36.71%

May. 16	Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials	MT
Apr. 25	Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Chengdu Olymvax Biopharmaceuticals Inc. has filed an IPO.

June 21, 2020 at 12:00 am EDT

Chengdu Olymvax Biopharmaceuticals Inc. has filed an IPO.

Security Name: A Shares
Security Type: Common Stock
Securities Offered: 40,530,000

Latest news about Chengdu Olymvax Biopharmaceuticals Inc.

Olymvax Biopharma's Flu Vaccine Gets China Nod for Clinical Trials	May. 16	MT
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Olymvax Biopharmaceuticals Withdraws Application for Combined Influenza Vaccine	Feb. 02	MT
Olymvax Biopharmaceuticals Grants Keyuan Xinhai Marketing Rights for Meningococcal Vaccines	Dec. 12	MT
Olymvax Biopharmaceuticals to Push Through Phase III Trial Into Recombinant Staphylococcus Aureus Vaccine	Nov. 21	MT
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Chengdu Olymvax Biopharmaceuticals Inc.(XSSC:688319) added to S&P Global BMI Index	23-09-18	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
Chinese healthcare stocks hit by stepped up anti-graft crackdown	23-08-09	RE
Olymvax Biopharma Gets Nod to Amend Packaging of Adsorbed Tetanus Vaccine	23-07-12	MT
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-28	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-17	CI
Chengdu Olymvax Biopharmaceuticals Inc.(SHSE:688319) added to Shanghai Stock Exchange A Share Index	22-06-08	CI
Chengdu Olymvax Biopharmaceuticals Inc.(SHSE:688319) added to Shanghai Stock Exchange Composite Index	22-06-08	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-27	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	22-02-22	CI
Chengdu Olymvax Biopharmaceuticals Inc. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-29	CI
Chengdu Olymvax Biopharmaceuticals Inc. has completed an IPO in the amount of CNY 400.4 million.	21-05-31	CI
Chengdu Olymvax Biopharmaceuticals Inc. has filed an IPO.	20-06-21	CI

Chart Chengdu Olymvax Biopharmaceuticals Inc.

Duration

Period

Chart Chengdu Olymvax Biopharmaceuticals Inc.

More charts

Chengdu Olymvax Biopharmaceuticals Inc is a China-based biopharmaceutical company mainly engaged in the research, development, production and sales of human vaccines. The Company's products mainly include adsorbed tetanus vaccine, Hib conjugate vaccine and tetanus toxoid concentrate stock solution. The Company's main customers are center for disease control and prevention (CDC) customers.

Sector

Pharmaceuticals

Calendar

2024-08-15 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Chengdu Olymvax Biopharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

Average target price

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
CHENGDU OLYMVAX BIOPHARMACEUTICALS INC.	-36.71%	560M
CSL LIMITED	+0.75%	92.38B
SAMSUNG BIOLOGICS CO.,LTD.	-3.03%	37.9B
BIOGEN INC.	-10.46%	33.73B
UCB	+73.76%	27.98B
BIOMARIN PHARMACEUTICAL INC.	-13.39%	15.86B
INCYTE CORPORATION	-1.08%	13.97B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-11.15%	11.67B
ALTEOGEN INC.	+169.04%	10.17B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-50.19%	10.04B

Biopharmaceuticals